AgingResearch.NewsJoin free

Phase 1/2RecruitingAge-related condition

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration (OVERTURE)

Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration

Sponsor
Eyconis INC. (Academic or other)
Enrolment
30 planned
Conditions
Neovascular (Wet) Age-Related Macular Degeneration
Interventions
EYC-0305
Ages
adults, older adults
Registry
NCT07587515

Full record on ClinicalTrials.gov

From the registry

This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

Primary outcomes

  • Incidence and severity of ocular treatment-emergent adverse events (TEAEs)
  • Incidence and severity of systemic treatment-emergent adverse events (TEAEs)

History

  1. Primary completion expected

  2. Last registry update

  3. Started

  4. Registered